Benefits
Acute ischemic stroke treatment (Russian regulatory approval)
Approved in Russia for acute ischemic stroke based on multiple clinical trials. Acute period treatment protocol: 12-18 mg/day intranasal for 10-14 days. Mechanism: neuroprotection via gene expression modulation (~3000+ DEGs identified in transcriptome studies), reduced inflammation, enhanced neuroplasticity, cerebrovascular protection. Russian-language literature shows improved functional recovery and motor performance. Limited Western RCT replication but consistent across Russian clinical trials over 2+ decades.
Hemispheric ischemic stroke
In patients in the acute period of hemispheric ischemic stroke, semax improved neurological outcomes, monitored with clinical rating scales, EEG mapping, and somatosensory evoked potentials. Limited by Russian-language literature accessibility.
Cognitive enhancement / nootropic effects
Early human work demonstrated that semax displays nootropic-like activity in healthy humans. Foundational evidence for cognitive enhancement claims. Limited methodology by modern standards but consistent with later preclinical and clinical evidence.
BDNF and TrkB regulation
Preclinical work demonstrated that semax regulates BDNF and TrkB expression in rat hippocampus. BDNF (brain-derived neurotrophic factor) is critical for neuronal survival, synaptic plasticity, learning, and memory. Mechanism for the cognitive and antidepressant effects observed clinically.
Optic nerve atrophy (Russian indication)
Approved in Russia for optic nerve atrophy and certain ophthalmological neurological conditions. Used as 1% solution drops. Mechanism: neuroprotection of retinal ganglion cells via BDNF, melanocortin pathway effects. Limited rigorous clinical evidence outside Russian literature.
Multi-mechanism neuroprotection (preclinical)
Extensive preclinical evidence for neuroprotection: dopaminergic and serotonergic transmission potentiation in striatum, neurotrophic effects in primary neuronal cultures, glutamate cytotoxicity protection, transcriptome-level effects on inflammatory and neurosignaling genes. Inherits melanocortin (α-MSH) properties via the ACTH(4-7) sequence — α-MSH has known neuroprotective properties.
Mechanism of action
Melanocortin receptor activation (via ACTH(4-7) fragment)
ACTH(4-7) sequence (Met-Glu-His-Phe) coincides with α-MSH (melanocyte-stimulating hormone) site. Activates melanocortin receptors providing α-MSH-like neuroprotective and anti-inflammatory effects without hormonal/toxic side effects of full ACTH. Mechanism distinct from typical nootropics.
BDNF and TrkB upregulation
Increases BDNF and TrkB receptor expression in hippocampus and other brain regions. BDNF is critical for synaptic plasticity, neuronal survival, learning, memory. Mechanism for cognitive enhancement and antidepressant effects.
Gene expression modulation (transcriptome-level effects)
RNA-Seq studies show semax affects expression of 1500-3000 differentially expressed genes (DEGs) under cerebral ischemia conditions. Compensates ~1171 genes' expression distortions caused by ischemia. Genes involved in inflammation, neurotransmission, neurogenesis, angiogenesis, protein kinase, growth factor pathways. Mechanism via complex transcriptional regulation.
Dopaminergic and serotonergic transmission potentiation
Potentiates dopamine and serotonergic neurotransmission in striatum and other brain regions. Mechanism for mood-enhancing and motivation effects. Provides theoretical basis for use in depression and ADHD-like cognitive symptoms.
Anti-inflammatory effects in CNS
Reduces pro-inflammatory cytokine expression in CNS during ischemia. Inherits α-MSH-like anti-inflammatory mechanisms. Mechanism for stroke neuroprotection and possibly broader CNS conditions involving neuroinflammation.
Neurotrophic effects in neuronal cultures
Direct neurotrophic effects in primary neuronal cultures — promotes neurite outgrowth, supports neuronal survival under stress conditions. Mechanism for neuroprotection and possibly recovery support.
Clinical trials
Russian-language study (Skvortsova VI, Lebedeva NV, Nasonov EL, Bryusov OS, Gusev EI 2001, Zh Nevrol Psikhiatr Im S S Korsakova S Suppl 1:23-29).
30 patients in acute period of hemispheric ischemic stroke received semax. Control group: 80 patients with analogous strokes treated by conventional therapy. Clinical rating scales, EEG with mapping, somatosensory evoked potentials monitored.
Demonstrated Semax efficacy in acute hemispheric ischemic stroke. Improved neurological outcomes vs control. Foundational Russian clinical trial supporting acute stroke approval. Russian-language publication limits Western methodological scrutiny.
Russian clinical study (Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN 2018, Zh Nevrol Psikhiatr Im S S Korsakova 118:61-68).
Patients at different stages of ischemic stroke (acute, recovery, late recovery) treated with semax.
Documented semax efficacy across different ischemic stroke stages with clinical improvement metrics. Foundational evidence for staged use protocols. Russian-language publication limits Western evidence assessment but consistent with broader semax stroke literature.
Mechanism study (Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF 2006, Brain Res 1117(1):54-60, doi:10.1016/j.brainres.2006.07.108).
Rat hippocampus tissue analyzed for BDNF and TrkB expression following semax administration.
Semax significantly upregulated BDNF and TrkB receptor expression in rat hippocampus. Foundational mechanism evidence for cognitive enhancement and neuroprotection. BDNF is critical neurotrophin for synaptic plasticity, learning, memory, and neuronal survival. Mechanism distinguishes semax from purely receptor-modulating nootropics.